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Abstract
Introduction Strict control of plasma glucose in diabetic and 
non-diabetic patients has been shown to improve outcome in 
several clinical settings. There is extensive evidence that 
glucose can stimulate the production of pro-inflammatory 
cytokines such as tumor necrosis factor (TNF)-a and IL-6, with 
no effect on the anti-inflammatory cytokine IL-10. W e 
hypothesized that strict glucose regulation results in a change in 
cytokine balance from a pro-inflammatory state to a more 
balanced anti-inflammatory condition. In a randomized 
controlled trial we studied the effect of strict glycemic control on 
the local and systemic pro-inflammatory and anti-inflammatory 
balance in non-diabetic patients undergoing elective coronary 
artery bypass grafting w ith cardiopulmonary bypass.
Methods After surgery patients were randomly assigned to 
intensive insulin therapy (blood glucose between 8 0  and 11 0  
mg/dl) or conventional insulin therapy (blood glucose less than 
200 mg/dl). At 0, 1, 2, 4, 8, 12, 16 and 24 hours after admission 
to the intensive care unit, plasma samples and samples from the 
mediastinal drains were obtained. W e measured the
concentrations of the pro-inflammatory cytokines TNF-a and IL-
6 and the anti-inflammatory cytokine IL-10 by enzyme-linked 
immunosorbent assay.
Results Both patient groups were comparable in 
demographics, clinical characteristics and peri-operative data. 
In the intensive treatment group, glucose levels were 
significantly lower than in the conventionally treated group. No 
differences were found between both groups in the 
concentrations of TNF-a, IL-6 and IL-10 in plasma samples or in 
fluid draining the mediastinal cavity. Levels of IL-6 and IL-10 
were significantly higher in mediastinal fluid samples than in 
plasma samples, suggesting a compartmentalized production of 
cytokines.
Conclusion The protective effect of intensive insulin therapy in 
patients after cardiac surgery with cardiopulmonary bypass is 
not related to a change in cytokine balance from a pro- 
inflammatory to an anti-inflammatory pattern. Systemic cytokine 
levels are not representative of the local inflammatory response.
Introduction
S tric t glycem ic contro l is increasingly recognized as an im por­
tant goal in a broad spectrum  of critically ill patients, even in 
the absence of pre-existing diabetes. A fte r myocardial infarc­
tion, stress hyperglycemia is associated w ith an increased risk 
of in-hospital mortality in both d iabetic and non-diabetic 
patients and increases the risk of congestive heart failure or 
cardiogenic shock in patients w ithout diabetes [1]. The D IG ­
AM I study dem onstrated that rapid improvement of metabolic
contro l in diabetic patients w ith myocardial infarction improves 
short-term and long-term outcom e [2,3]. Intensive insulin ther­
apy is thought to increase the success rate of thrombolysis 
and preserves myocardial function [4,5]. The recently pub­
lished DIGAMI 2 trial failed to support the hypothesis that insu­
lin treatment improves survival and morbidity in diabetic 
patients after myocardial infarction, possibly because the tar­
get blood glucose levels in the treatment group were never 
reached [6]. However, this trial confirm ed that glucose is a
CABG =  coronary artery bypass grafting; ICU =  intensive care unit; IL =  interleukin; NF =  nuclear factor; TNF =  tumor necrosis factor. R790
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strong and independent factor of long-term mortality in these 
patients. In cardiac surgery patients, hyperglycemia was found 
to be an independent post-operative risk factor fo r the devel­
opment of hyperlactatemia and associated w ith increased 
morbidity and mortality [7,8]. A  meta-analysis of all randomized 
studies using glucose-insulin-potassium  therapy in cardiac 
surgery patients indicated that such therapy m ight considera­
bly improve post-operative recovery of contractile function and 
reduce the incidence of atrial arrhythmias [9]. Some studies 
even show  a survival benefit [10]. In critically ill patients in a 
surgical intensive care unit (ICU), maintenance of blood glu­
cose levels between 80 and 110 m g/dl resulted in a 42%  
reduction in mortality compared w ith conventional treatment 
aiming at blood glucose levels between 180 and 200 m g/dl 
[11]. More than 60%  of the patients in this study had also 
recently had cardiac surgery.
H o w  stric t contro l of blood glucose reduces m orbidity and 
mortality is unknown, but the mechanism may be related either 
to a d irect effect of normalization of hyperglycemia or to the 
concom itantly higher insulin levels. P ost hoc  multivariate logis­
tic  regression analysis of the study by van den Berghe et a l. 
suggests that the lowered blood glucose level rather than the 
insulin dose is related to the reduction in mortality [12,13]. In 
this study [11] sep tic  patients showed the largest reduction in 
mortality, suggesting that strict glucose regulation m ight influ­
ence the inflammatory response.
Hyperglycem ia has a strong impact on host defense. Acute, 
short-term hyperglycemia affects all major com ponents of 
innate immunity [14]. Neutrophil activity is reduced, leading to 
decreased chemotaxis, decreased phagocytosis, decreased 
bacterial killing and overproduction of free radicals [15-17]. In 
addition to changes in cellular function, other com ponents of 
the innate immune response contribute to the pro-inflamma­
tory state in hyperglycemia. In vitro, human monocytes show  a 
glucose-dependent increase in tum or necrosis factor (TNF)-a 
and IL-6 production [18-20]. Healthy volunteers have an 
increase in the pro-inflammatory cytokines IL-6, TNF-a and IL- 
18 when the plasma glucose level is acutely raised by glucose 
infusion while endogenous insulin secretion is blocked with 
octreotide [21]. Patients w ith hyperglycemia on admission to 
the ICU had increased levels of IL-6 and IL-10, although after 
multivariate analysis only IL-6 was associated w ith hyperglyc­
emia [22 ].
Studies of cytokine responses in critically ill patients are 
potentially confounded by the absence of a well-defined time 
of onset and differences in the etio logy and severity of the d is­
ease. Cardiac surgery is associated w ith the developm ent of a 
system ic inflammatory reaction w ith increased cytokine con­
centrations. Inflammation after cardiac surgery is believed to 
be caused mainly by contact of blood w ith the artificial surface 
of the extracorporeal circuit, and also by ischemia-reperfusion 
injury, and the operative trauma [23,24]. It has been sug­
gested that the release of pro-inflammatory cytokines into the 
circulation is important in the pathogenesis of post-operative 
myocardial dysfunction [25-28]. W e  studied the effect of strict 
glycem ic contro l on the local and system ic pro-inflammatory 
and anti-inflammatory cytokine balance in cardiac surgery 
patients after cardiopulm onary bypass. W e considered car­
diac surgery w ith cardiopulm onary bypass to be a suitable 
clinical model of inflammation w ith a well-defined preset time 
of onset and etiology of the insult, in contrast to other clinical 
models of inflammation such as sepsis. W e hypothesized that 
s tric t glucose regulation m odulates cytokine production in 
these patients, leading to a shift toward a more anti-inflamma­
tory pattern [29].
Methods
Study population
W e performed a randomized contro lled trial in non-diabetic 
patients undergoing elective coronary artery bypass grafting 
(CABG ). The local Institutional Review Board approved the 
protocol. W ritten informed consent was obtained from each 
patient on the day before surgery. All patients aged 18 years 
or older scheduled for elective C A B G  were eligible for the 
study. Patients were excluded if they had a history of diabetes, 
fasting blood glucose levels above 100 m g/dl on the day 
before surgery, myocardial infarction within 4 weeks before 
surgery, card iogenic shock or renal failure (serum creatinine 
level above 1.7 m g/dl). Patients were also excluded if they had 
used any m edication within 4 weeks before surgery known to 
modulate the inflammatory response (for example non-steroi­
dal anti-inflammatory drugs or steroids) or when there were 
clinical signs of infection or inflammatory disease. The use of 
low-dose salicylates was allowed. Patients undergoing off­
pump cardiac surgery were excluded. During surgery no blood 
glucose concentrations were measured, and none of the 
patients received insulin before admission to the ICU. C ard i­
opulmonary bypass was performed w ith a prim ing solution 
containing gelatin (Gelofusine®), mannitol, albumin, N aH C O 3, 
C aC l2 and heparin. A fte r weaning from cardiopulmonary 
bypass, patients were given protamine to neutralize the 
heparin. Heparin antagonization was identical in both groups.
Study design
Patients were randomly assigned to receive intensive or con­
ventional treatment. Assignm ents to the treatm ent groups 
were made w ith the use of sealed envelopes. In the intensive 
treatment group, patients received insulin (Actrapid HM; Novo 
Nordisk, Copenhagen, Denmark) intravenously to maintain 
blood glucose levels between 80 and 110 mg/dl. In the con­
ventional treatment group, insulin therapy was given when 
blood glucose levels exceeded 200 m g/dl. Similarly to the trial 
by van den Berghe et al. [11], treatm ent started immediately 
on admission to the ICU. B lood glucose levels were measured 
hourly and adjusted according to a nomogram based on the 
study by van den Berghe et al. [11]. On admission, all patients 
were infused continuously w ith 3.75 g of intravenous glucose
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Table  1
Base line  cha racte ris tics  o f pa tien ts
Characteristic Conventional treatment (n =  10) Intensive treatment (n =  10) P
Male sex, number (%) 8 (80) 10 (100)
Age, years 63.2 ±  6.6 65.2 ±  8.7 0.57
Body mass index 26.4 ±  3.1 28.4 ±  4.1 0.23
Duration of operation, minutes 181 ±  52 160 ±  34 0.31
Time on cardiopulmonary bypass, minutes 90 ±  30 83 ±  27 0.57
Blood glucose on admission, mg/dl 96.7 ±  19.6 113.3 ±  14.9 0.05
Parsonnet score 3.0 ±  4.2 5.5 ±  4.2 0.20
APACHE II score 9.2 ±  2.7 9.0 ±  3.4 0.88
Values are means ±  SD. APACHE, Acute Physiology and Chronic Health Evaluation.
per hour. Blood samples fo r the measurement of systemic 
cytokine concentration and drain samples from the mediastinal 
cavity (local cytokine release) were taken on arrival in the ICU 
and at 1, 2, 4, 8, 12, 16 and 24 hours after admission.
Cytokine analysis
Blood and samples from the tubes draining the mediastinal 
cavity were immediately centrifuged fo r 15 minutes at 2,000 g  
at 4°C, and serum and supernatants were stored at -80°C  until 
measurement in a single batch. Concentrations of TNF-a, IL-6 
and IL-10 were measured in accordance w ith the m anufac­
turer's instructions w ith a commercial sandw ich-type enzyme- 
linked im m unosorbent assay (PeliKine; Sanquin, Amsterdam, 
The Netherlands).
plications were reported. APAC H E (Acute Physiology and 
Chronic Health Evaluation) II and Parsonnet scores were com ­
parable on arrival in the ICU. Blood glucose levels on adm is­
sion were slightly higher in the intensive treatm ent group than 
in the conventional treatm ent group (mean ±  SD 114.4 ±  15.1 
versus 97.6 ±  19.8 m g/dl; p  =  0.05).
No major com plications occurred during the post-operative 
stay in any of the patients. Post-operative time on the ventilator 
and the time in the ICU were comparable in both groups 
(Table 2). Both groups had sim ilar increases in creatinine 
kinase levels as a global measure of tissue damage. Equal 
amounts of erythrocyte and platelet transfusions were adm in­
istered in both treatm ent arms.
Statistical analysis
Power calculation was based on clinically relevant changes in 
serum IL-6 levels. In previous studies a standard deviation of 
14 to 16%  of baseline values was found [30-32]. An insulin­
mediated decrease of 15%  in IL-6 or a 15%  increase in IL-10 
was considered to indicate a clinically relevant change in the 
pro-inflammatory and anti-inflammatory balance. W ith  an esti­
mated SD of 15%  and a significance level a o f  0.05, a sample 
size of nine patients per group was calculated to reach a 
power of 90% . W e therefore included 10 patients per group 
in the present study. Changes in cytokine levels over time were 
analyzed w ith one-way analysis of variance. Differences 
between groups were analyzed w ith two-way analysis of vari­
ance. p  <  0.05 was considered statistically significant. All data 
are expressed as median (interquartile range unless otherwise 
stated).
Results
Study population
A total of 20 patients were enrolled in the study. The clinical 
and dem ographic characteristics of the two groups at rand­
omization are shown in Table 1. No differences were found 
w ith respect to age, body mass index, duration of operation or 
time on cardiopulm onary bypass. No major perioperative com ­
Blood glucose control
In the intensive treatm ent group all patients required exoge­
nous insulin, whereas in the conventionally treated group only 
one patient received a low dose of insulin when blood glucose 
exceeded 200 m g/dl (Figure 1a). Blood glucose levels were 
significantly lower in the intensive treatm ent group than in the 
conventional treatment group (p <  0 .003) (Figure 1 b). 
Hypoglycemia (defined as a blood glucose level of 40  m g/dl 
or less) did not occur in any of the patients. The rise in mean 
glucose levels in the placebo group, together w ith the escalat­
ing insulin dosage in the stric t contro l group, suggests 
increasing insulin resistance after surgery. This may be 
explained by increasing catecholam ine concentrations, 
because the increased glucose levels coincided w ith tapering 
of the anesthetic agents. Hemodynamic parameters such as 
blood pressure, heart rate, urine production and administration 
of inotrop ic agents were comparable between the groups 
(data not shown).
TNF-a, IL-6 and IL-10 concentration in serum
System ic concentration of TNF-a did not change statistically 
during the first post-operative day (data not shown). IL-6 
increased post-operatively w ith maximum values 2 to 4 hours 
after admission (p <  0.001), fo llowed by a gradual decline
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Table  2
P os t-ope ra tive  data
Event Conventional treatment (n =  10) Intensive treatment (n =  10) P
Time between end of surgery and admission to the ICU, minutes 11.4 ±  7.7 18.4 ±  9.1 0.10
Time in ICU, hours 20.3 ±  2.5 22.1 ±  1.8 0.09
Time on ventilator, hours 9.8 ±  4.6 11.2 ±  6.6 0.65
Creatinine kinase, U/l
On admission 342 ±  371 273 ± 171 0.60
At 16 hours after admission 649 ±  483 684 ±  499 0.88
Erythrocyte transfusion, units 1.67 ±  1.5 1.10 ±  0.88 0.32
Platelet transfusion, units 0.63 ±  0.74 0.33 ±  0.50 0.35
Values are means ±  SD. ICU, intensive care unit.
(Figure 2a). The anti-inflammatory cytokine IL-10 was 
increased on admission and showed a second peak at 12 
hours after admission (p =  0.002) (Figure 2 b). No differences 
were found between the conventional and intensive treatment 
group w ith regard to the pattern and levels of systemic 
cytokine production. The ratio of IL-6 to IL-10 increased in the 
first hours w ith a maximum at 2 hours after admission (p <  
0 .001) and showed a rapid decline afterwards (Figure 2 c).
TNF-a, IL-6 and IL-10 concentration in samples from the 
mediastinal cavity
Cytokines were measured in flu ids from the mediastinal drains. 
IL-6 levels from the mediastinal cavity increased and reached 
a maximum at 8 hours after admission (p <  0 .001) (Figure 3a). 
Levels of IL-6 in the tubes draining the mediastinal cavity were 
about 1,000-fold higher than the values measured in blood. IL- 
10 concentrations showed a peak at 12 hours after admission 
(p <  0 .001) and were about 10 tim es higher in the samples 
from the mediastinum than in the system ic levels (Figure 3 b). 
No differences were found in the mediastinal levels of TNF-a, 
IL-6 and IL-10 between the treatm ent groups. The IL-6/IL-10 
ratio had a peak at 4 hours after admission, fo llowed by a sec­
ond rise at 12 hours after admission (p <  0 .001) (Figure 3 c).
Discussion
The main conclusion from the present study is that stric t g lu­
cose regulation does not alter cytokine concentrations in the 
plasma and in the mediastinal cavity in patients after CABG . 
S tric t glucose contro l also had no effect on activation of the 
terminal com plem ent complex or leukocyte numbers (data not 
shown). These results suggest that the beneficial effect of 
intensive insulin therapy in patients after cardiac surgery is not 
mediated by changes in cytokine balance.
The beneficial effects of stric t glucose contro l in the study by 
van den Berghe et al. [11] are supported by a study in diabetic 
patients undergoing cardiac surgery in which continuous insu­
lin therapy reduced the risks of death and wound infections by 
57%  and 66% , respectively [33]. Multivariate logistic regres­
sion analysis has shown that the beneficial effects of stric t g lu­
cose contro l in the study by van den Berghe et al. [11] was 
related mainly to an improvement in dyslipidem ia [34]. H ow ­
ever, this po s t hoc  analysis included only patients adm itted for
7 days or longer and is therefore clearly different from our 
uncom plicated C AB G  patients. It is nevertheless possible that 
the pro-inflammatory effects of increased fatty acid levels also 
have a role in acute illness. Infusion of trig lycerides in healthy 
volunteers acutely increased NF-k B binding activity and p65 
expression in circulating m onocytes [35]. Activation of NF-k B 
induces an inflammatory response by the increased transcrip­
tion of genes that are involved in the production of pro-inflam ­
matory cytokines and adhesion molecules. Fatty acids might 
therefore be involved in an acute increase in the inflammatory 
response. Short-term  effects of lipid modulation on m orbidity 
have also been shown in the Myocardial Ischemia Reduction 
w ith Aggressive Cholesterol Lowering (MIRACL) study [36]. 
In this multicentre trial, patients w ith unstable angina pectoris 
or non-Q-wave myocardial infarction treated w ith atorvastatine 
had a lower mortality, lower incidence of recurrent ischemia, 
non-fatal myocardial infarction and cardiac arrest than pla­
cebo-treated controls. Further analysis of these patients sug­
gests that the beneficial effect of this statin therapy m ight be 
related to modulation of the cellular inflammatory response 
[37].
The second important finding of our study was the com part­
mentalized cytokine production, w ith levels of IL-6 and IL-10 
that were significantly higher in mediastinal fluid samples than 
in plasma samples. Compartmentalized cytokine production 
has been dem onstrated in animal models [38,39] and several 
clinical settings [40-42]. O ur results clearly demonstrate local 
production of cytokines in the mediastinal cavity after cardiac 
surgery. The myocardium is a major source of cytokines. Sam ­
pling of blood from the coronary sinus in patients undergoing
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F igure  1 F igure  2
Insulin dosage andglucose concentration are significantly different 
between the treatment groups. Insulin dosage per hour (a) and glucose 
concentration in serum (b) in the intensive and conventional treatment 
group after admission to the intensive care unit. Points are median 
values.
C AB G  showed increased levels of TNF-a and IL-6 than in 
serum [43,44]. In patients w ith signs of myocardial necrosis 
the inflammatory response originates from the myocardium 
itself [45,46].
Systemic cytokine concentrations are comparable between the treat­
ment groups. Concentration of IL-6 (a) and IL-10 (b) at different time 
points after admission to the intensive care unit. (c) The ratio of IL-6 to 
IL-1 0 in serum is expressed as arbitrary units. No significant differences 
are found between both treatment groups. Points are median values.
Compartmentalized cytokine production is also suggested in a 
study in which elective percutaneous coronary intervention 
w ith and w ithout cardiopulm onary bypass and card iopulm o­
nary bypass supported C A B G  were compared [47]. Patients 
undergoing C A B G  had much higher IL-6 levels than those 
undergoing the other interventions, suggesting that the local 
surgical trauma contributes more to the inflammatory response 
than the system ic reaction to cardiopulm onary bypass. O ur 
data, in concordance w ith these studies, suggest that the
operative trauma to the myocardium and its surrounding tis ­
sues is the major source of cytokine production after cardiac 
surgery. It is unlikely that the system ic inflammatory response 
syndrome response elicited by the extracorporal bypass has a 
major role because IL-6 and IL-10 production in the m ediasti­
nal cavity exceeded system ic production 1,000-fo ld and 10­
fold, respectively. The local operative trauma and possibly 
ischemia-reperfusion injury is a more likely explanation for the 
higher local cytokine concentrations. These results also imply
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F igure  3
Cytokine production is highly compartmentalized. Concentration of IL-6 
(a) and IL-10 (b) in mediastinal fluid at different time points after admis­
sion to the intensive care unit. (c) The ratio of IL-6 to IL-10 in mediasti­
nal fluid is expressed as arbitrary units. No significant differences are 
found between both treatment groups. IL-6 and IL-10 levels are signifi­
cantly higher in the mediastinal fluid samples than in plasma samples, 
indicating local production. Points are median values.
that studies trying to unravel the mechanisms underlying the 
effect of glucose and insulin on inflammatory processes 
should preferably take place in the com partm ent of interest. In 
this context it would be interesting to study cytokine concen­
trations in the coronary sinus under various conditions.
O ur results are in conflict w ith several other studies showing 
that hyperglycemia increases the production of pro-inflamma­
tory cytokines [21 ,22 ]. A lthough differences between glucose 
levels in the two treatm ent groups were highly significant, 
hyperglycemia in the conventionally treated patients was 
milder than in several other studies and this m ight have 
resulted in an impaired trigger for the immune system to 
change the balance. As a result of modern peri-operative tech­
niques, the system ic inflammatory response syndrome 
induced by surgery and cardiopulm onary bypass was relatively 
mild, as is reflected by relatively low APACH E II scores in both 
groups. In the study by van den Berghe et al. [11] the largest 
reduction in mortality was found in patients w ith multiple organ 
failure and sepsis. In septic patients the system ic inflammatory 
response results in very high concentrations of pro-inflamma­
tory cytokines. It m ight be that under these circum stances 
stric t glucose contro l can shift the cytokine balance toward a 
more anti-inflammatory pattern.
One might speculate that the timing, duration and dosage of 
insulin could have influenced the results of th is study. Institut­
ing insulin therapy before admission to the ICU would proba­
bly not have changed the cytokine balance, because median 
blood glucose levels on admission were within the target 
range of insulin treatment, and blood glucose levels became 
different between the groups only after 4 hours of treatment. It 
is unlikely that insulin treatm ent beyond the first 24  hours 
would have influenced the cytokine balance significantly, 
because after the first 18 hours glucose levels started to nor­
malize in the contro l group, and cytokine concentrations are 
known to decline rapidly after the first day of surgery. Because 
the beneficial effects of post-operative glucose contro l are 
most probably related to lowered blood glucose levels rather 
than the insulin dose, it is not to be expected that increasing 
levels of insulin will change the inflammatory response [12,13].
Conclusion
S tric t glucose regulation in acute and critically ill d iabetic and 
non-diabetic patients reduces morbidity and mortality in sev­
eral clinical settings. The exact mechanisms underlying these 
acute beneficial effects of intensive insulin therapy remain 
unknown. O ur study shows that a change in balance between 
pro-inflammatory and anti-inflammatory cytokines does not 
explain the beneficial effects seen in ICU patients after cardiac 
surgery. The importance of a compartmentalized cytokine p ro­
duction implicates that studies that focus on system ic effects 
of glucose and insulin should be interpreted w ith caution.
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Key messages
• The beneficial effects of stric t glucose contro l cannot 
be explained by a change in cytokine balance.
• Cytokine production in patients after cardiac surgery is 
highly compartmentalized.
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